Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

Halozyme Announces First Clinical Dosing Of Janssen's Daratumumab Using ENHANZE(TM) Technology

PR Newswire November 4, 2015

Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference

PR Newswire November 3, 2015

Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze(TM) Technology

PR Newswire October 29, 2015

Halozyme To Host Third Quarter 2015 Financial Results Conference Call

PR Newswire October 19, 2015

Halozyme Appoints Michael J. Labarre As Chief Scientific Officer

PR Newswire August 24, 2015

Halozyme Reports Second Quarter 2015 Financial Results

PR Newswire August 10, 2015

UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery

PR Newswire August 6, 2015

Halozyme Appoints Jeffrey W. Henderson To Board

PR Newswire August 5, 2015

Halozyme to Host Second Quarter 2015 Financial Results Conference Call

PR Newswire August 3, 2015

Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer

PR Newswire July 31, 2015

Eisai and Halozyme Sign Collaboration Agreement to Investigate Halaven® (Eribulin) and PEGPH20 in Metastatic Breast Cancer

PR Newswire July 30, 2015

Halozyme Therapeutics To Present At The JMP Securities 2015 Life Sciences Conference

PR Newswire June 19, 2015

Halozyme Announces Plans For CFO Transition, Names Laurie Stelzer CFO

PR Newswire June 5, 2015

Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie

PR Newswire June 3, 2015

Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients

PR Newswire May 31, 2015

Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment

PR Newswire May 27, 2015

Halozyme Therapeutics To Present At The UBS 2015 Global Health Care Conference

PR Newswire May 12, 2015

Halozyme Reports First Quarter 2015 Financial Results

PR Newswire May 11, 2015

Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference

PR Newswire May 7, 2015

Halozyme To Host First Quarter 2015 Financial Results Conference Call

PR Newswire May 4, 2015